Haleon Plc · LSE:HLN
Haleon — Q3 2026 Earnings Presentation
22 slides from Haleon's earnings presentation, Oct 29, 2026
Slide 1: 2026 Third quarter trading statement
2026 Third quarter trading statement October 2026
Slide 2: Disclaimer
Disclaimer This presentation contains certain statements that are, or may be deemed These forward-looking statements and views may be based on a number of to be, “forward-looking statements” (including for purposes of the safe assumptions and, by their nature, involve known and unknown risks, harbor
Slide 3: Brian McNamara, CEO - Third quarter results
Brian McNamara CEO 2026 Third quarter results
Slide 4: Weaker than expected Q3 performance: 2.6% organic revenue growth
Weaker than expected Q3 performance: 2.6% organic revenue growth Performance impacted by: category softness including Respiratory Health and classification change on Centrum OTC registered products in China Emerging markets: High-teens growth in India, improving picture in Middle East & Africa and m
Slide 5: Third quarter 2026 revenue
Third quarter 2026 revenue £2.9bn 2.6% 2.1% /0.5% Q3 revenue Organic revenue growth1 Price / Volume Mix Q3 organic revenue1: Delivering on capital allocation priorities • Continued strong performance across Oral Health • Announcing a further £500m share buyback to • Category softness including Respi
Slide 6: Recent trends in cold and flu
Recent trends in cold and flu Weekly market cold and flu (million units) 50 C&F season 45 2025-26 40 2026-27 35 30 25 20 15 Winter season Off season 10 Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Source: Local week data, 11 markets (US, UK, IT, RU, PL, SK, CZ, HU, FR, GER, NTH) 6
Slide 7: 2026 guidance
2026 guidance Organic revenue growth1 of c. 2.5% High-single digit adjusted operating profit growth2 Other modelling considerations Net Interest, Tax, and Translational Foreign non-controlling interest Exchange • Net interest cost expected to be • Translational FX expected to be c.£255m broadly neut
Slide 8: Scale proven capabilities faster and apply them consistently across the business
Scale proven capabilities faster and apply them consistently across the business 01 02 03 04 Scale Commercial Revenue growth Marketing Innovation execution management effectiveness Revamped innovation Standardise and scale Scale advanced pricing and Investment in audiences, pipeline. Unlocking claim
Slide 9: Dawn Allen, CFO - Third quarter results
Dawn Allen CFO 2026 Third quarter results
Slide 10: Q3 2026 organic revenue growth: +2.6%
Q3 2026 organic revenue growth : +2.6% 1 ORG1 (0.1)% 0.0% +2.6% £2,868m Organic revenue growth impacted by Net M&A Translational sequential slowdown in North America 2.1% foreign and Europe and impact of raw material exchange classification change on Centrum OTC 0.5% registered products in China £2,
Slide 11: Global portfolio delivering growth
Global portfolio delivering growth Organic. Q3 2026 Revenue. revenue growth1 £m % Oral Health 930 8.8 VMS 423 (0.5) Pain Relief 657 0.5 Respiratory Health 499 (2.0) Digestive Health 245 2.5 Therapeutic Skin Health and Other 114 (0.7) TOTAL 2,868 2.6 1. Definition/reconciliation of IFRS to non-IFRS r
Slide 12: North America
North America 34% of Q3 2026 Revenue Q3 performance: • Good growth driven by new innovation launches, stronger £992m retail execution and enhanced in-store activations • Double digit Oral Health growth, outpacing the market by c. 3x underpinned by innovations Q3 2026 Revenue • VMS broadly flat, with
Slide 13: Europe
Europe 28% of Q3 2026 Revenue Q3 performance: • Consumer environment remains challenging across £798m Europe, with subdued market volumes particularly in Germany and Central & Eastern Europe • Oral Health grew mid-single digit, supported by Q3 2026 Revenue innovation and strong in-market execution •
Slide 14: APAC
APAC 21% of Q3 2026 Revenue Q3 performance: • China grew mid-single digit; SEAT grew low single digit £593m against a softer consumer backdrop related to Middle East conflict • Oral Health grew double digit, led by China Q3 2026 Revenue • VMS declined slightly, with double-digit Caltrate growth offs
Slide 15: International
International 17% of Q3 2026 Revenue Q3 performance: • High-teens growth in India, supported by increased £485m Sensodyne penetration and strong execution, improving growth in MEA and a flat performance in LatAm • Oral Health up double digit with strength in India and MEA Q3 2026 Revenue • Double di
Slide 16: Brian McNamara, CEO - Third quarter results
Brian McNamara CEO 2026 Third quarter results
Slide 17: Weaker than expected Q3 performance: 2.6% organic revenue growth
Weaker than expected Q3 performance: 2.6% organic revenue growth Performance impacted by: category softness including Respiratory Health and classification change on Centrum OTC registered products in China Emerging markets: High-teens growth in India, improving picture in Middle East & Africa and m
Slide 18: Appendix
Appendix
Slide 19: Glossary
Glossary Organic revenue growth Organic revenue represents revenue, as determined under IFRS, but excluding the impact of − Prior year and current year organic revenue growth exclude revenue attributable to divestments, acquisitions, manufacture and supply agreements (MSAs) relating to divestments M
Slide 20: Historic quarterly growth across the categories
Historic quarterly growth across the categories Organic revenue growth1 2025 2026 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Oral Health 6.6% 8.7% 6.9% 9.3% 7.9% 8.3% 6.2% 8.8% VMS 0.9% 0.9% 4.9% 1.2% 1.9% 1.7% 2.2% (0.5)% Pain Relief 2.6% 2.5% 3.7% 0.5% 2.3% (0.3)% 4.6% 0.5% Respiratory Health 0.7% (2.0)% (1.8)% (4.6
Slide 21: Reconciliation of Q3 organic growth
Reconciliation of Q3 organic growth Product Categories Therapeutic Oral Pain Respiratory Digestive Skin Health 2026 vs 2025 (%) Health VMS Relief Health Health & Other Total Revenue Growth 7.3 0.2 1.5 (2.2) 2.1 0.9 2.5 Organic Adjustments - - - - - 2.0 0.1 Effect of Exchange Rates 1.5 (0.7) (1.0) 0.
Slide 22: Q3 2026 results
Q3 2026 results Jo Russell Rakesh Patel Head of Investor Relations Director Investor Relations [email protected] [email protected] +44 7787 392441 +44 7552 484646